Verteporfin photodynamic therapy in the rat model of choroidal neovascularization: angiographic and histologic characterization.
OBJECTIVE
To develop a model of verteporfin photodynamic therapy (PDT) for experimental choroidal neovascularization CNV in the rat.


METHODS
A laser injury model was used to induce experimental CNV in rats. The transit and accumulation of the photosensitizer verteporfin was assessed angiographically in CNV lesions, to determine the optimal time for delivery of light energy. The CNV lesions were then treated with verteporfin PDT, with two doses of verteporfin (3.0 and 6.0 mg/m(2)) and four activating doses of light energy (10, 25, 50, and 100 J/cm(2)). Closure of the CNV was assessed both angiographically and histologically. Verteporfin PDT was also performed on areas of normal choroid and retina at the two verteporfin doses and four light energy doses. The effect of these treatments on these structures was also assessed angiographically and histologically.


RESULTS
Peak verteporfin intensities in the CNV were detected at 15 to 20 minutes after intravenous injection. Rates of closure of the CNV varied as a function of the dose of verteporfin and of the activating light energy. Angiographic closure of the CNV correlated with damage to the neovascular complex, as seen with light and electron microscopy. Damage to areas of normal choroid and retina treated with verteporfin PDT also varied as a function of the verteporfin and light energy doses.


CONCLUSIONS
Verteporfin PDT for experimental CNV in the rat is a feasible, effective, and reproducible model that can be used for testing the efficacy of adjunctive therapy to verteporfin PDT.
Zacks
David N
DN
Retina Service and Angiogenesis Laboratory, Massachusetts Eye and Ear Infirmary, Harvard Medical School, 243 Charles Street, Boston, MA 02114, USA.
Ezra
Eric
E
Terada
Yoshiko
Y
Michaud
Norman
N
Connolly
Edward
E
Gragoudas
Evangelos S
ES
Miller
Joan W
JW
D000818:Animals; D002829:Choroid / Q000187:drug effects / Q000473:pathology / Q000601:surgery; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000473:pathology*; D005451:Fluorescein Angiography; D053685:Laser Therapy; D023421:Models, Animal; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011166:Porphyrins / Q000627:therapeutic use*; D051381:Rats; D011914:Rats, Inbred BN; D012160:Retina / Q000187:drug effects / Q000473:pathology; D000077362:Verteporfin
D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin